# Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Source: https://onco.cc/trials/nct03659448/  
OnCo record `nct03659448` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SGM-101 in colorectal cancer, now recruiting.

## Summary

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer is a phase 3 interventional study registered as NCT03659448, led by Surgimab, and recruiting on the registry. Official title: Multicenter, Open-label, Randomised, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer. Planned enrolment is 300 participants (estimated). The study started in 2019-06-17 and primary completion is expected in 2024-11. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT03659448
- Phase: 3
- Setting: Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
- Sponsor: Surgimab
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT03659448: https://clinicaltrials.gov/study/NCT03659448

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [SGM-101](https://onco.cc/drugs/sgm-101/)
- companies: [Surgimab](https://onco.cc/companies/surgimab/)

---
JSON: https://onco.cc/api/v1/entities/nct03659448.json